Serum levels of resistin are higher, while adiponectin lower in psoriasis patients in comparison with healthy controls and correlate with psoriasis severity, therefore, can be used as potential biomarkers for psoriasis development and treatment effectiveness2. This evidence concerns the gene ADIPOQ and psoriasis.